Ferguson Wellman Capital Management Inc. Has $47.44 Million Stake in Johnson & Johnson (NYSE:JNJ)

Ferguson Wellman Capital Management Inc. lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 47.1% during the 3rd quarter, Holdings Channel.com reports. The fund owned 292,735 shares of the company’s stock after selling 260,916 shares during the period. Ferguson Wellman Capital Management Inc.’s holdings in Johnson & Johnson were worth $47,441,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in JNJ. Innealta Capital LLC bought a new stake in Johnson & Johnson during the second quarter worth approximately $27,000. Highline Wealth Partners LLC acquired a new stake in Johnson & Johnson in the 3rd quarter worth $31,000. Mowery & Schoenfeld Wealth Management LLC increased its stake in Johnson & Johnson by 58.7% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after acquiring an additional 91 shares during the period. Morton Brown Family Wealth LLC raised its stake in shares of Johnson & Johnson by 400.0% in the third quarter. Morton Brown Family Wealth LLC now owns 250 shares of the company’s stock valued at $41,000 after purchasing an additional 200 shares in the last quarter. Finally, MFA Wealth Advisors LLC acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at $43,000. 69.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

JNJ has been the subject of several recent analyst reports. TD Securities dropped their price objective on Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Daiwa Capital Markets lowered Johnson & Johnson from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Wells Fargo & Company raised their target price on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Finally, Sanford C. Bernstein raised their price target on shares of Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Seven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $175.00.

Johnson & Johnson Trading Down 0.3 %

Shares of NYSE:JNJ traded down $0.39 during midday trading on Thursday, reaching $152.85. The company’s stock had a trading volume of 200,797 shares, compared to its average volume of 6,963,744. The firm has a 50 day moving average price of $161.82 and a two-hundred day moving average price of $155.99. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The firm has a market capitalization of $368.00 billion, a price-to-earnings ratio of 22.18, a PEG ratio of 2.71 and a beta of 0.53. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The company had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. Johnson & Johnson’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.66 EPS. As a group, analysts forecast that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.25%. Johnson & Johnson’s payout ratio is currently 71.78%.

Insider Activity

In related news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.